Journal of Clinical Medicine· 2026Q2
Indications for Biological Treatment Combined with Allergen-Specific Immunotherapy: Who Is It Really Intended for?
- 0citations
- Q2SCImago
- 2026year
Short summary
Combining biological agents like omalizumab and dupilumab with allergen-specific immunotherapy (AIT) shows promise for allergic asthma and food desensitization, particularly during high-risk dose escalation phases.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Immunology and Allergy
Immunology and AllergyMedicine